Loading page
Loading page
Loading substance route
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Brotizolam has recognized potential for abuse and is classified as habit-forming. Abuse was significant enough in Hong Kong during the late 1980s and 1990s to warrant government reclassification as a Dangerous Drug, with regulatory controls subsequently extended to all benzodiazepines.
Physical dependence can develop with regular use. Treatment is recommended for only 2-4 weeks for severe insomnia. Mild rebound insomnia may occur when treatment is stopped, indicating physiological adaptation to the drug.
Hallucinations and paradoxical reactions including aggression, anxiety, and violent behavior are listed as less common side effects. These psychiatric disturbances appear to be uncommon at recommended doses.
Brotizolam was first patented in 1974. The compound's synthesis was subsequently documented by Weber, Bauer, Danneberg, and Kuhn through a 1978 United States patent. The substance entered clinical practice a decade after its initial patent in 1984, finding adoption primarily in European markets and
Approved for medical use and available by prescription.
Brotizolam has not received approval for sale or prescription use in Canada.
Reclassified as a Dangerous Drug by the Pharmacy and Poisons Board in October 1990 following concerns about benzodiazepine abuse. Detailed records are required for supply and dispensing alongside formal prescriptions.
Approved for sale and available through medical prescription.
Approved for sale and dispensed as a prescription medication.
Available as an approved prescription medication for therapeutic use.
Approved for sale and available as a prescription medication.
Brotizolam has not been approved for medical use or sale. It remains unavailable as a prescription medication in the US market.
Available as an approved prescription medicine for therapeutic applications.
Approved for medical use and available through prescription from licensed practitioners.
Approved for sale and available by prescription for medical purposes.
Approved for medical use and available as a prescription medication.
Approved for sale and available as a prescription medication for therapeutic use.
Approved for sale as a prescription medication for legitimate medical purposes.
Not approved for sale or medical use in the UK. The substance is not available through legitimate pharmaceutical channels.
12 sources cited